Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by bfwon May 30, 2018 6:03pm

155 Views

Post# 28101865

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:50 million US dollars debentures

The Notes will be offered by way of a short form prospectus in all of the provinces of Canada and may also be offered by way of private placement in the United States

SPCEO1 wrote:

bfw wrote:

juniper88 wrote: Theratechnologies intends to use the net proceeds of the Offering to fund payments totaling US$23,850,000 due under the Third Amendment of the EMD Serono Termination Agreement, the approval and commercialization of Trogarzo(TM) in Europe and other jurisdictions and for other general corporate purposes, including potential acquisitions in the execution of its business plan. Conversion price is US$14.85, or about CAD $19.12

I guess RBC will be covering TH in a month or so.

Hopefully, most of this is spoken for by US investors.

Bfw

It is not eligible to be sold to US investors. RBC's analyst is in the US and hopefully will push out a report as a result of this deal. That would be a huge positive step. Perhaps they will then do a NASDAQ listing with no offering associateed with it because they would at elast get one US analyst covering the stock.